ALNY vs. TEVA: Alnylam Pharmaceuticals vs. Teva Pharmaceutical Stock Comparison

Company Profile

Alnylam Pharmaceuticals (ALNY) and Teva Pharmaceutical (TEVA) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ALNY is classified in Biotechnology while TEVA is classified in Pharmaceuticals.

Alnylam Pharmaceuticals (ALNY) trades as ordinary local shares, while Teva Pharmaceutical (TEVA) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both companies show strong equity returns, but Alnylam Pharmaceuticals (ALNY) at 138.07% is the standout with ROE above its industry range; Teva Pharmaceutical (TEVA) at 6.65% also sits in the top quartile.

Alnylam Pharmaceuticals (ALNY) at 52.85% converts revenue to bottom-line profit above its industry’s benchmark range, while Teva Pharmaceutical (TEVA) at 2.94% keeps roughly the typical share for its industry.

Both Alnylam Pharmaceuticals (ALNY) at 23.72% and Teva Pharmaceutical (TEVA) at 27.40% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Alnylam Pharmaceuticals (ALNY) at 65.19% sits in the top revenue growth quartile, while Teva Pharmaceutical (TEVA) at 4.31% is closer to the peer norm — faster top-line expansion for ALNY.

Neither Alnylam Pharmaceuticals (ALNY) nor Teva Pharmaceutical (TEVA) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Financial Strength

Alnylam Pharmaceuticals (ALNY) at 2.48 keeps current ratio within its industry’s typical mid-range, while Teva Pharmaceutical (TEVA) at 0.95 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for TEVA.

Both balance sheets lean debt-heavy versus peers, but TEVA is more stretched: Alnylam Pharmaceuticals (ALNY) at 0.83 sits in the higher-leverage quartile and Teva Pharmaceutical (TEVA) at 2.13 is above its industry benchmark range.

Financial Strength Metrics

Dividends

Neither Alnylam Pharmaceuticals (ALNY) nor Teva Pharmaceutical (TEVA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Alnylam Pharmaceuticals (ALNY) nor Teva Pharmaceutical (TEVA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

Alnylam Pharmaceuticals (ALNY) at 7.88 sits in the cheaper P/E ratio quartile, while Teva Pharmaceutical (TEVA) at 99.09 trades above its peer range — a wide earnings-valuation gap relative to industry peers.

Teva Pharmaceutical (TEVA) at 2.89 sits in the cheaper P/S ratio quartile while Alnylam Pharmaceuticals (ALNY) at 4.17 prices around its industry’s middle — TEVA costs less per dollar of sales, though read it alongside growth and margins.

On P/B ratio, both Alnylam Pharmaceuticals (ALNY) at 5.79 and Teva Pharmaceutical (TEVA) at 6.23 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics